AbbVie Wins Two FDA Breakthrough Tags for Cancer Drug

What Happened

AbbVie has received two FDA Breakthrough Therapy Designations for its investigational cancer drug telisotuzumab adizutecan, covering colorectal cancer and non-small cell lung cancer. The designations, reported this week, place the antibody-drug conjugate among a select group of experimental therapies the U.S. Food and Drug Administration has identified as potentially offering substantial improvement over existing treatments for serious conditions.

Background

Breakthrough Therapy Designation is a formal FDA program created to expedite the development and review of drugs that treat serious or life-threatening conditions. To qualify, preliminary clinical evidence must indicate that the drug may demonstrate substantial improvement on at least one clinically significant endpoint over available therapy. The designation does not constitute approval, but it does entitle the developer to more intensive FDA guidance during clinical development and may support a faster review timeline.

Telisotuzumab adizutecan is an antibody-drug conjugate, a class of cancer treatment that combines a targeting antibody with a cytotoxic payload to deliver cell-killing agents directly to tumor cells. AbbVie, headquartered in North Chicago, Illinois, is one of the largest pharmaceutical companies in the United States by revenue. The company's portfolio is anchored by immunology and oncology products, and it has been expanding its oncology pipeline through acquisitions and internal development.

Non-small cell lung cancer is the most common form of lung cancer and accounts for approximately 85 percent of all lung cancer diagnoses globally, according to the American Cancer Society. Colorectal cancer is the third most commonly diagnosed cancer in the United States. Both indications represent large patient populations with significant unmet medical need, particularly in later lines of therapy where standard treatment options are limited.

The Drug in Focus

Telisotuzumab adizutecan, also referred to in clinical literature as Teliso-ADC, targets c-Met, a protein encoded by the MET gene that is overexpressed in several tumor types. Overexpression of c-Met has been associated with poor prognosis and resistance to existing therapies in both lung and colorectal cancers. The antibody component of the drug is designed to bind to c-Met-expressing tumor cells, while the adizutecan payload is intended to induce cell death upon internalization.

AbbVie has been advancing telisotuzumab adizutecan through multiple clinical trials. The two Breakthrough Therapy Designations are based on clinical data submitted to the FDA, though the specific trial data underpinning the designations were not detailed in the reports available at publication time.

Regulatory Context

Since the Breakthrough Therapy Designation program launched in 2012, the FDA has granted the status to hundreds of investigational drugs. Drugs that receive the designation are not guaranteed approval, and sponsors are still required to complete adequate and well-controlled clinical trials demonstrating safety and efficacy. However, the designation has historically been associated with faster development timelines for drugs that ultimately reach approval.

AbbVie joins other major oncology developers that have used the Breakthrough Therapy pathway for antibody-drug conjugates in recent years. The ADC class has attracted significant investment from large pharmaceutical companies, with several products gaining approval across breast, bladder, and lung cancer indications.

What Happens Next

AbbVie is expected to continue advancing telisotuzumab adizutecan through ongoing clinical trials in both indications, with future regulatory submissions to be informed by the FDA guidance made available through the Breakthrough Therapy Designation process.